Table 4.
First-Line Treatment Response Among (a) Patients with Newly Diagnosed AML and (b) All Patients with R/R AML, and Those with R/R AML and FLT3WT, FLT3MUT, and Unknown FLT3 Mutation Status
| (a) | |||||
| Therapy | All newly Diagnosed Patients (N = 853) | ||||
| Patients Who Received Treatment(s), n (%) | Treatment Response, n (%) | Relapsed, n (%) | Refractory, n (%) | ||
| CR/CRi Not Yet Achieved/Observed | Ever Achieved CR/CRi | ||||
| Induction therapy | 853 (100) | 102 (12.0) | 751 (88.0) | 234 (27.4) | 55 (6.4) |
| Consolidation therapy | 743 (87.1) | 61 (8.2) | 682 (91.8) | ||
| HSCT | 63 (7.4) | 9 (14.3) | 54 (85.7) | ||
| (b) | |||||
| Therapy | All R/R diagnosed patients (N = 289) | ||||
| Patients who received treatment(s), n (%) | Treatment response, n (%) | Time from treatment initiation to first relapse after initial treatment (days), mean (SD) [median (IQR)] | Time from first documented CR/CRi to first relapse after initial treatment (days), mean (SD) [median (IQR)] | ||
| CR/CRi not yet achieved/observed | Ever achieved CR/CRi | ||||
| Induction therapy | 289 (100) | 59 (20.4) | 230 (79.6) | 358.0 (241.5) [306.5 (254.2)] | 314.3 (242.6) [252.0 (268.0)] |
| Consolidation therapy | 230 (79.6) | 29 (12.6) | 201 (87.4) | ||
| HSCT | 12 (4.2) | 4 (33.3) | 8 (66.7) | ||
| Therapy | FLT3WT (N = 58) | ||||
| Patients who received treatment(s), n (%) | Treatment response, n (%) | Time from treatment initiation to first relapse after initial treatment (days), mean (SD), [median (IQR)] | Time from the first documented CR/CRi to the first relapse after the initial treatment (days), mean (SD) [median (IQR)] | ||
| CR/CRi not yet achieved/observed | Ever achieved CR/CRi | ||||
| Induction therapy | 58 (100) | 3 (5.2) | 55 (94.8) | 366.9 (220.3) [331.5 (235.8)] | 321.8 (220.1) [291.0 (212.8)] |
| Consolidation therapy | 55 (94.8) | 4 (7.3) | 51 (92.7) | ||
| HSCT | 1 (1.7) | 0 (0) | 1 (100) | ||
| Therapy | FLT3MUT at R/R (N = 14) | ||||
| Patients who received treatment(s), n (%) | Treatment response, n (%) | Time from treatment initiation to first relapse after initial treatment (days), mean (SD), [median (IQR)] | Time from first documented CR/CRi to first relapse after initial treatment (days), mean (SD), [median (IQR)] | ||
| CR/CRi not yet achieved/observed | Ever achieved CR/CRi | ||||
| Induction therapy | 14 (100) | 2 (14.3) | 12 (85.7) | 320.0 (172.5) [294.0 (123.8)] | 271.0 (174.3) [242.0 (126.0)] |
| Consolidation therapy | 12 (85.7) | 1 (8.3) | 11 (91.7) | ||
| HSCT | 2 (14.3) | 2 (100) | 0 (0) | ||
| Therapy | Unknown FLT3 mutation status at R/R (N = 217) | ||||
| Patients who received treatment(s), n (%) | Treatment response, n (%) | Time from treatment initiation to first relapse after initial treatment (days), mean (SD), [median (IQR)] | Time from first documented CR/CRi to first relapse after initial treatment (days), mean (SD), [median (IQR)] | ||
| CR/CRi not yet achieved/observed | Ever achieved CR/CRi | ||||
| Induction therapy | 217 (100) | 54 (24.9) | 163 (75.1) | 357.8 (252.7) [293.0 (283.0)] | 314.9 (254.3) [235.0 (292.0)] |
| Consolidation therapy | 163 (75.1) | 24 (14.7) | 139 (85.3) | ||
| HSCT | 9 (4.1) | 2 (22.2) | 7 (77.9) | ||
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; HSCT, hematopoietic stem-cell transplantation; FLT3, FMS-like tyrosine kinase-3; HSCT, hematopoietic stem-cell transplantation; MUT, mutated; R/R, relapsed/refractory; SD, standard deviation; WT, wild type.